Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pibrentasvir
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Pibrentasvir is a direct-acting antiviral agent used in the treatment of chronic hepatitis C virus (HCV) infection. It is classified as an HCV NS5A inhibitor, acting by blocking the NS5A protein, which plays a critical role in viral RNA replication and virion assembly. Pibrentasvir exhibits pan-genotypic activity against HCV genotypes 1 through 6 and is effective even against strains resistant to other NS5A inhibitors. It is most commonly administered as part of a fixed-dose combination with glecaprevir (an HCV NS3/4A protease inhibitor) under the brand name Mavyret, developed for patients who have failed previous therapies or are treatment-naive[2][4][5]. The drug was developed by AbbVie.
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on pibrentasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pibrentasvir.